Oral immunotherapy represents a promising curative treatment for immunoglobulin E (IgE)-mediated food allergy (FA), reducing the risk of reactions following accidental exposure to the allergen, potentially achieving desensitization, defined as the increase in the threshold of reaction to food allergen while on treatment, and improving patients' and parents' quality of life.1 According to the European Academy of Allergy and Clinical Immunology (EAACI) guidelines, oral immunotherapy (OIT) is recommended as an active treatment for persistent cow's milk (CM), hen's egg, or peanut allergies for children from around 4 to 5 years of age to increase the threshold of reactivity.1 Efficacy and safety of OIT have been demonstrated by different studies.2 However, adverse reactions (ARs) may occur during OIT. These may be mild and localized, such as oral allergy syndrome (OAS), or more rarely systemic and severe, possibly including anaphylactic reactions.1 The primary outcome of our study was to evaluate the prevalence and severity of anaphylaxis during OIT in a cohort of pediatric patients. The secondary outcome was to define in what percentage such an event resulted in protocol discontinuation.
Anaphylaxis during OIT and its impact on treatment adherence: A retrospective study
Galletta, Francesca;Passanisi, Stefano;Manti, Sara
;
2024-01-01
Abstract
Oral immunotherapy represents a promising curative treatment for immunoglobulin E (IgE)-mediated food allergy (FA), reducing the risk of reactions following accidental exposure to the allergen, potentially achieving desensitization, defined as the increase in the threshold of reaction to food allergen while on treatment, and improving patients' and parents' quality of life.1 According to the European Academy of Allergy and Clinical Immunology (EAACI) guidelines, oral immunotherapy (OIT) is recommended as an active treatment for persistent cow's milk (CM), hen's egg, or peanut allergies for children from around 4 to 5 years of age to increase the threshold of reactivity.1 Efficacy and safety of OIT have been demonstrated by different studies.2 However, adverse reactions (ARs) may occur during OIT. These may be mild and localized, such as oral allergy syndrome (OAS), or more rarely systemic and severe, possibly including anaphylactic reactions.1 The primary outcome of our study was to evaluate the prevalence and severity of anaphylaxis during OIT in a cohort of pediatric patients. The secondary outcome was to define in what percentage such an event resulted in protocol discontinuation.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
